Banning cheaper generic forms of a dangerous drug sounds like a worthy idea But the Food and Drug Administrations decision to bar generic OxyContin may also push patients towards less effective drugs without eliminating the risk of addiction experts say Obviously theres a cost issue says   president of the American Academy of Pain Medicine Not having generics means this type of medication is going to be more expensive On Tuesday the FDA   that it wont approve generic versions of the original formulation of OxyContin a longacting narcotic pain medication which went off patent that day Normally the end of the patents life would open the door to generics But drugmakers must now develop their own abuseresistant versions if they want to compete for a share of the lucrative market In    replaced the original OxyContin with an abuseresistant form in an effort to reduce deaths and overdoses caused by the powerful pain medication which was licensed in  From  to  deaths involving prescription opioid painkillers more than tripled according to the federal Centers for Disease Control and Prevention In  Purdue pleaded guilty to federal charges that it misbranded the drug by claiming that it was safer and less addictive than shortacting narcotic drugs like Vicodin and Percocet The new version of OxyContin includes an ingredient a polymer that makes it harder to crush and snort or inject to get a quick heroinlike high When the new version was introduced Purdue pulled the original OxyContin off the market The patent on the new version runs until  Thats good news for Purdue Even though OxyContin sales dropped after the abusedeterrent version was introduced the medicine still accounts for onethird of the market for prescription painkillers with  billion in sales according to IMS Health The average cost for a pill is  or  per bottle of  according to Purdue The issue is really about the generic and the availability issue says Dr Joe Ross an assistant professor at the Yale School of Medicine who studies drug and device safety Why do they essentially get a patent extension when they had an unsafe drug on the market for many years Why would the FDA reward them The high cost of OxyContin does drive prescribing decisions Webster says and doctors may switch to methadone and other lessconvenient options when a patients insurance wont cover OxyContin which provides extended pain relief It would be disastrous to market generic OxyContin without making it abuseresistant Webster says There should be no opioids on the market that dont have some abusedeterrent formulation Some abusers of opioids have   from OxyContin and Opana a longacting prescription opioid made by   since the abusedeterrent forms were released But about onequarter of abusers say theyve figured out how to defeat the deterrent according to a    in the   Just because a pill is abusedeterrent doesnt mean its harmless A pill thats harder to snort or inject isnt necessarily less addictive says   head of psychiatry at Maimonides Medical Center in New York who studies policy on opioid drugs People also get addicted by swallowing pills he notes One of my concerns is that this new rule could set up an arms race for the pharmaceutical companies to create abusedeterrent versions because they have patent protection Kolodny told Shots Youll see marketing to prescribers that these pills are less addictive That could potentially make things worse